New Trade Alert: Nuvilex Inc (OTCMRKTS:NVLX)
Hope you had a wonderful trading day. the pick we promise to bring you after the close today is ready. With a strong momentum going into the stock we think we can see it break new highs.
We at Nuvilex believe and uphold our motto, “Good for You, Good for the Environment.”
Founded in 1996, as a Nevada Corporation, DJH International., Inc., the Company was renamed eFoodSafety.com, Inc. following acquisition of Global Procurement Systems, Inc. in 2000. Ozone Safe Food, Inc. was acquired in 2003 and set an early mission to provide methods and products for sterilization with worldwide software tracking of safely marketed fruits and vegetables.
In 2004, eFoodSafety.com began trading on the OTC Bulletin Board (OTCBB) under the symbol EFSF. Within a year, Knock-Out Technologies, Ltd. (KOT) and MedElite, Inc were acquired. Through use of organic, non-toxic, food-based ingredients, KOT developed products designed for the treatment of nutritional deficiencies, diseases, and environmental purposes, including Nuvilex’s flagship products Cinnergen and Cinnechol, and the developmental products Citroxin and Oraphyte. MedElite, on the other hand, owned Talsyn™-CI/bid Scar Cream, a product used for treatment of keloids, erythema, and scar management, and NumaDerm™ cosmetics, now being reintroduced from the Nuvilex developmental drawer and available shortly.
As a result of these acquisitions, the Company’s entire strategy was changed forever to become one of developing and marketing products for improving the health and well-being of our customers and are part of our true and basic mission, “Good for You, Good for the Environment.”
After Ozone Safe Food, Inc. was successfully sold in 2005, eFoodSafety.com, Inc. formed four wholly-owned subsidiaries each responsible for development, manufacture and marketing of a major product including:
- Cinnergen, Inc. for Cinnergen™, a non-prescription nutritional supplement to promote healthy glucose metabolism, and is expanding sales for this valuable natural product.
- Cinnechol, Inc. for Cinnechol™, a non-prescription nutritional supplement to promote healthy cholesterol, triglyceride metabolism, and promotion of cardiovascular health, and has reinitiated sales for this great natural product.
- purEffect, Inc., for purEffect™, a four-step, non-prescription acne treatment. In 2006, the marketing rights to purEffect™ were first licensed and later sold to Charlston Kentrist Direct 41, Inc. [CK41] and 2009. It is a pleasure to recognize CK41 in successfully marketing purEffect™ (http://www.pureffect.com/), with support from testimonials as well as famous individuals including Carmen Electra, Tiffany Giardina, Larzz, Molly Sims, and Estella Warren. Nuvilex will be receiving royalties in the future and have and continue to look forward to a good relationship with CK41 and their management.
- I-Boost, Inc. for a food supplement bar designed to improve the effectiveness of the immune system, which was eventually closed due to insufficient consumer interest.
In 2009, eFoodSafety.com, Inc. acquired Freedom-2 Holdings, Inc., the manufacturer of Infinitink®, a heavy-metal-free tattoo ink designed to be more easily removed than traditional inks. As a result, eFoodSafety.com, Inc. was renamed to Nuvilex, Inc. and changed to NVLX on the Bulletin Board (OTCBB). Between September 2010 and February 2011, a new management team was assembled and as a result, Nuvilex (NVLX) was listed as fully reporting on the OTCQB stock exchange where it presently trades at approximately 4M shares per day and has hit new 2 year highs over $0.076.
Since January, the new management at Nuvilex has begun substantial efforts to add to its success by expanding into the biotechnology arena. As a result, a new acquisition of a pancreatic cancer treatment technology will initiate our growth and expansion into this area. The present status of this includes completed initial clinical trials in Europe with multiple directions for forward movement which are presently in the planning and initiation stages. Your new management, through their ongoing activities, believes will create a paradigm shift for Nuvilex into becoming a true Biotechnology and Natural Products leader. These actions are well underway and should provide excellent opportunities going forward. Dr. Robert Ryan stated, “Many more dramatic and exciting events are still to enter into our story, yet, they will be in keeping and allow us to stay true to our philosophy and motto…”
“Good for You, Good for the Environment.”
We At Nuvilex Are…..
a vibrant, exciting and energized company with a strong legacy in the development of products with a particular focus on natural components and biotechnology for human, animal and environmental health. In addition to Cinnergen™, Cinnechol™, Talsyn™, and Infinitink® mentioned above, our line of natural products includes Cinnsational™ for reduction of detrimental alcohol effects, NumaDerm™ cosmetic products, Reme-Flu™, a flu-combating 2-part homeopathic regimen registered with the FDA and licensed from Legacy Biotechnologies, Inc., and Virgin® Ink, a heavy-metal-free tattoo ink. Citroxin™ and Oraphyte™, antimicrobial and antinematodal agents are being worked on and planned for advancement by the end of 2011.
In addition to solidifying and expanding our natural product lines, Nuvilex is making important strides to expand its presence into the biotechnology arena. Already in 2011, the initial early development of the Company’s first all-natural anticancer agent, Alternia™, was announced. Plans are being created to move Alternia™ forward in our pipeline. In addition, Nuvilex is in the final stages of acquiring valuable cell technology to allow for individualized treatment of a variety of human diseases, including pancreatic cancer, one of the most deadly forms of cancer, unfortunately usually discovered in a late-stage and thus making it a difficult-to-treat disease.
Nuvilex’s mission has been and continues to be to develop, manufacture, and market products that are “Good for You, Good for the Environment.”
Nuvilex is a cutting edge, innovative Company whose aim is to initiate a paradigm shift, generating revenue at the same time as creating cancer and other cell related solutions to treat important human diseases, such as pancreatic cancer while retaining our connections to natural products. The present effort underway will give rise to dramatic advances in cancer therapy and benefit millions of people worldwide.
All of our products have been, and will continue to be, developed through the use of natural products and/or biotechnology in order to assist people in the pursuit of a healthy body and to improve the environment around us all. We invite you to learn more about Nuvilex and our products and plans. Thank you for visiting. Have a great day!
Nuvilex, Inc. Readies Pancreatic Cancer Treatment for Expanded Phase II Clinical Trials
SCOTTSDALE, AZ — (OTC Disclosure and News Service) — June 6, 2011 — Nuvilex, Inc. (OTCQB: NVLX) announced today it is aggressively engaging the steps necessary to use its encapsulated cell technology for pancreatic cancer in expanded Phase II clinical trials in the United States, Europe and Australia. The Company’s objective is to have a protocol submitted to the regulatory agencies in these countries as quickly as possible.